Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas

Modern Pathology

Volumn 10, Issue 9, 1997, Pages 917-920

  Kanter Lewensohn, Lena ^a   Hedblad, Mari Anne ^b   Wejde, Johan ^a   Larsson, Olle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Bcl 2; Immunohistochemistry; Malignant melanoma; MIB 1; Proliferation; Spitz nevus

Indexed keywords

ANTIBODY;

ARTICLE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

ANTIGENS, NUCLEAR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELANOMA; NEVUS, EPITHELIOID AND SPINDLE CELL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030762690     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Barnhill RL. Spitz nevi and variants. In: Barnhill RL, editor. Pathology of melanocytic nevi and malignant melanoma. Newton, MA: Butterworth-Heinemann; 1995. p. 97-130.
2. Smith K, Skelton H, Lupton G, Graham J. Spindle cell and epitheloid cell nevi with atypia and metastasis. Am J Surg Pathol 1989;13:931-6.
3. Kanter L, Blegen H, Wejde J, Lagerlšf B, Larsson O. Utility of a proliferation marker in distinguishing between benign nevocellular nevi and nevocellular nevus-like lesions with malignant properties. Melanoma Res 1995;5:345-50.
4. Fogt F, Vortmeyer AO, Tahan SR. Nuclear organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions. Am J Dermatopathol 1995;17:12-7.
5. McGovern VJ. Melanoma. Histological diagnosis and prognosis. New York: Raven Press; 1983. p. 3-24.
6. Niemann T, Argenyi Z. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen. Am J Dermatopathol 1993;15: 441-5.
7. Korsmeyer SJ. bcl-2: an antidote to programmed cell death. Cancer Surv 1992;15:105-18.
8. van den Oord JJ, Vandeghinste N, DeLey M, DeWolf-Peeters C. bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145:294-300.
9. Evan G, Wyllie AH, Gilberts CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
10. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359:554-6.
11. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992;359:552-4.
12. Morales-Ducret CBJ, van de Rijn M, Smoller BR. bcl-2 expression in melanocytic nevi. Arch Dermatol 1995;131: 915-8.
13. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea SR. Immunohistochemical expression of bcl-2 in melanomas and intradermal nevi. J Cutan Pathol 1994;21:393-7.
14. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995;146:643-9.
15. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995;8: 150-4.
16. Cerroni L, Soyer P, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7-11.